Volume 21, Number 11—November 2015
Research
Carbapenem-Resistant Enterobacteriaceae in Children, United States, 1999–2012
, John P. Renschler, Sumanth Gandra, Robert A. Weinstein, Ramanan Laxminarayan, and for the Centers for Disease Control and Prevention Epicenters Program
Table 4
CRE and non-CRE multidrug-resistant isolates by species, The Surveillance Network–USA database, 1999–2012*
| Organism | Non-CRE, no. MDR†/no tested‡ (%) | CRE, no. MDR†/no. tested‡ (%) |
|---|---|---|
| All species | 11,718/314,573 (3.73) | 127/263 (48.29) |
| Escherichia coli | 8,402/238,709 (3.52) | 29/57 (50.88) |
| Klebsiella pneumoniae | 1,223/23,263 (5.26) | 74/83 (89.16) |
| Proteus mirabilis | 390/19,458 (2.00) | 0/2 (0.00) |
| Enterobacter species§ | 775/16,867 (4.59) | 20/98 (20.41) |
| Serratia marcescens | 513/9,629 (5.33) | 4/15 (26.67) |
| Citrobacter species¶ | 415/6,647 (6.24) | 0/8 (0.00) |
*CRE, carbapenem-resistant Enterobacteriaceae. CRE is defined as resistance to all tested third-generation cephalosporins (ceftriaxone, cefotaxime, or ceftazidime), and nonsusceptiblity to >1 carbapenem (ertapenem, imipenem, meropenem, or doripenem). For bacteria with intrinsic imipenem nonsusceptibility (P. mirabilis), the CRE criteria required nonsusceptibility to >2 of the carbapenems listed. ICU, intensive care unit.
†These isolates were nonsusceptible to >1 drug from each of the following 3 drug classes: aminoglycosides (gentamicin, tobramycin, amikacin), β-lactams (aAmpicillin/sulbactam, piperacillin/tazobactam), fluoroquinolones (ciprofloxacin), and trimethoprim/sulfamethoxazole.
‡These isolates were tested against >1 drug from each of the following 3 drug classes: aminoglycosides (gentamicin, tobramycin, amikacin}, β-lactams (ampicillin/sulbactam, piperacillin/tazobactam), fluoroquinolones (ciprofloxacin, and trimethoprim/sulfamethoxazole.
§E. aerogenes and E. cloacae.
¶C. freundii and C. koseri.